Utah researchers launch worldâs largest gene-mapping study for kids, seek 50,000 volunteers
Doctors hope to find genetic markers to identify cancer, heart disease and other disorders.
(Photo courtesy of Intermountain Healthcare) Dr. John Bonkowsky, director of Intermountain Primary Childrenâs Hospitalâs Center for Personalized Medicine, is one of the researchers involved in Intermountain s HerediGene: Children s Study, the largest genetic mapping study of children ever. The study is seeking 50,000 volunteers.
  | Feb. 3, 2021, 9:40 p.m.
The largest genetic mapping study involving children is being launched in Utah, and researchers want 50,000 children and their parents to volunteer to take part.
âThe technical term, I believe, is humongous. This is huge. This is a game changer,â said Dr. Josh Bonkowsky, director of the Center for Personalized Medicine at Primary Childrenâs Hospital.
Künstliche Intelligenz soll COPD-Patienten mit richtiger diepresse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from diepresse.com Daily Mail and Mail on Sunday newspapers.
EU Reporter
EAPM: Europe Beating Cancer Plan takes disease in hand, but lung cancer screening must be stressed more
Published 2 months ago
Good morning health colleagues, and welcome to the European Alliance for Personalised Medicine (EAPM) update. Naturally, there is much focus in these troubled times on the coronavirus pandemic that is sweeping the world, but EAPM is still very much also focused on the pandemic of cancer, particularly ahead of the formal launch of the Europe Beating Cancer Plan on 3 February. Read on for more information,
writes EAPM Executive Director Dr. Denis Horgan.
EAPM round table
Registration is open for the European Alliance for Personalised Medicine (EAPM) ‘virtual’ event, held online next week, on 3 February, 9h30 – 11h CET. The round table is entitled
ROCHESTER, Minn. In a new study published in
Circulation, Mayo Clinic researchers provide the first preclinical, proof-of-concept study for hybrid gene therapy in long QT syndrome, a potentially lethal heart rhythm condition.
Researchers demonstrated its potential therapeutic efficacy in two in vitro model systems using beating heart cells reengineered from the blood samples of patients with 1 long QT syndrome. They targeted the whole KCNQ1 gene rather than specific LQT1-causative mutations, making this study applicable to all patients with long QT syndrome 1, regardless of their specific disease-causing variant.
The team consisted of Mayo Clinic researchers from Mayo Clinic s: Department of Cardiovascular Medicine.